THERAPEUTIC EFFECTS AND ADVERSE EVENTS OF SINGLE DOSE OF INTRAVITREAL TRIAMCINOLONE ACETONIDE INJECTION IN MACULAR EDEMA

BRIGHTY MATHEW; SYAM SREEDHARAN; PADMASREE KAMALA MADHAVAN; APARNA RETNAYYAN

doi:10.22159/ajpcr.2022.v15i11.45870

Authors

BRIGHTY MATHEW Department of Pharmacology, Government Medical College, Kottayam, Kerala, India. https://orcid.org/0000-0001-9305-227X
SYAM SREEDHARAN Department of Pharmacology, Government Medical College, Kottayam, Kerala, India.
PADMASREE KAMALA MADHAVAN Department of Ophthalmology, Government Medical College, Kottayam, Kerala, India.
APARNA RETNAYYAN Department of Pharmacology, Government Medical College, Kottayam, Kerala, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i11.45870

Keywords:

Macular edema, Diabetic retinopathy, Retinal vein occlusion, Triamcinolone acetonide

Abstract

Objective: The objective of the study was to study the therapeutic effects and adverse events of single dose of intravitreal triamcinolone acetonide (TA) in macular edema (ME).

Methods: This prospective observational study was conducted for a period of 18 months in a tertiary care hospital. A total of 100 patients who received intravitreal injection of TA 4 mg were followed up within 1 month of injection and thereafter monthly for 3 months. Therapeutic effect was noted by improvement in visual acuity and reduction in macular thickness. Safety was assessed based on adverse events reported during the study period. The quantitative variables were analyzed by paired t-test and the qualitative variables by Wilcoxon signed-rank test and Chi-square test.

Results: The mean age was 58.66±11.21 years with majority of patients (46%) in 46–60 age group. Diabetic retinopathy was the most common etiology. Fifteen patients experienced improvement in vision within 1 month, 51, 84, and 91 patients had better visual acuity after 1, 2, and 3 months, respectively, which were statistically significant (p=0.001). The mean macular thickness of 497.79±115.08 at baseline reduced to 448.62±112.48 within 1 month which further reduced to 383.72±105.79, 327.33±86.49, and 263.83±68.68 at the end of the 1st, 2nd, and 3rd months, respectively (p=0.001). The adverse events of rise in intraocular pressure, cataract, redness, pain, floaters, and subconjunctival hemorrhage were not found to be statistically significant (p>0.05).

Conclusion: Intravitreal TA injection may be an effective and safe treatment option for ME due to various etiologies.

Downloads

Download data is not yet available.

References

Kent D, Vinores SA, Campochiaro PA. Macular oedema: The role of soluble mediators. Br J Ophthalmol 2000;84:542-5. doi: 10.1136/ bjo.84.5.542, PMID 10781524

Sharareh B, Gallemore R, Taban M, Onishi S, Wallsh J. Recalcitrant macular edema after intravitreal bevacizumab is responsive to an intravitreal dexamethasone implant in retinal vein occlusion. Retina 2013;33:1227-31.

Jyothi SL, Gupta NV. Diabetic retinopathy: An inclusive review on current treatment and management approaches. Asian J Pharm Clin Res 2018;11:54-61. doi: 10.22159/ajpcr.2018.v11i11.26949

Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984;91:1-9. doi: 10.1016/S0161-6420(84)34337-8, PMID 6709312

Bowling B. Kanski’s Clinical Ophthalmology. 8th ed. Vol. 630. Netherlands: Elsevier Health Sciences; 2015.

National Eye Institute. Facts About Macular Edema. Bethesda: National Eye Institute. Available from: https://www.nei.nih.gov/health/macular_ edema/fact_sheet at 1.04 pm [Last accessed on 2019 Jun 19].

Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol 1985;103:1796-806.

Argon laser photocoagulation for macular edema in branch vein occlusion. The branch vein occlusion study group. Am J Ophthalmol 1984;98:271-82. doi: 10.1016/0002-9394(84)90316-7, PMID 6383055

Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group M report. Ophthalmology 1995;102:1425-33. doi: 10.1016/s0161- 6420(95)30849-4, PMID 9097788

Vedantham V, Kim R. Intravitreal injection of triamcinolone acetonide for diabetic macular edema: Principles and practice. Indian J Ophthalmol 2006;54:133-7. doi: 10.4103/0301-4738.25840, PMID 16770036

Couch SM, Bakri SJ. Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Clin Ophthalmol 2009;3:41-7. doi: 10.2147/opth.s4477, PMID 19668543

Pickrell A, Harris A, Ngo S, Amireskandari A, Stewart E, Siesky B. Delivery of intraocular triamcinolone acetonide in the treatment of macular edema. Pharmaceutics 2012;4:230-42. doi: 10.3390/ pharmaceutics4010230, PMID 24300190

Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000;84:1064-7. doi: 10.1136/bjo.84.9.1064, PMID 10966969

McCuen BW, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-8. doi: 10.1016/0002-9394(81)90013-1, PMID 7246702

Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal injection of triamcinolone: Results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-40. doi: 10.1001/archopht.122.3.336, PMID 15006845

Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999;27:431-2. doi: 10.1046/j.1440-1606.1999.00238.x, PMID 10641903

Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-6. doi: 10.1016/ s0002-9394(03)00483-5, PMID 14597028

Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: A comprehensive review. Retina 2004;24:676- 98. doi: 10.1097/00006982-200410000-00002, PMID 15492621

Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster CS. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm 2005;13:205-12. doi: 10.1080/09273940590933511, PMID 16019680

Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-8. doi: 10.1016/j.ophtha.2004.10.042, PMID 15808249

Edema M. The American Society of Retina Specialists. Available from: https://www.asrs.org/patients/retinal-diseases/20/macular-edema at 9.10 pm [Last accessed on 2019 Sep 13].

Ahmed JI, Puzari DB, Sarkar DJ. Clinical evaluation of intravitreal triamcinolone acetonide in diabetic macular oedema. Sch J App Sci 2016;4:2657-64.

Jain AK, Jain S, Pandey DJ, Sharma R. To evaluate the effect of intravitreal injection of triamcinolone acetonide in recalcitrant macular disorders. Asian J Pharm Clin Res 2015;1:157-60.

Narasimhaiah VB, Tomy R, Swamy S, Naik SP. Efficacy of intravitreal triamcinolone acetonide in macular oedema in posterior segment conditions. J Evid Based Med Healthc 2017;4:3942-7. doi: 10.18410/ jebmh/2017/788

Chellakumar V, Vijai C. A Randomised, comparative study of grid laser and subthreshold micropulse diode laser in the treatment of diffuse diabetic maculopathy. Asian J Pharm Clin Res 2015;8:240-3.

Cekiç O, Chang S, Tseng JJ, Barile GR, Del Priore LV, Weissma H, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005;25:851-5.

Agarwal S, Raman R, Paul PG, Rani PK, Uthra S, Gayathree R, et al. Sankara nethralaya-diabetic retinopathy epidemiology and molecular genetic study (SN-DREAMS 1): Study design and research methodology. Ophthal Epidemiol 2005;12:143-53. doi: 10.1080/09286580590932734, PMID 16019696

García Fernández M, García Alonso A, Fonollá Gil M, Rodríguez Villa S. Intravitreal triamcinolone acetonide use in diffuse persistent diabetic macular edema. Arch Soc Esp Oftalmol 2011;86:314-9. doi: 10.1016/j.oftal.2011.05.018, PMID 22004576

Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: An optical coherence tomography study. Br J Ophthalmol 2004;88:1131-6. doi: 10.1136/bjo.2004.041707, PMID 15317702

Tewari HK, Sony P, Chawla R, Garg SP, Venkatesh P. Prospective evaluation of intravitreal triamcinolone acetonide injection in macular edema associated with retinal vascular disorders. Eur J Ophthalmol 2005;15:619-26.

Islam MS, Vernon SA, Negi A. Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years. Eye (Lond) 2007;21:321-3. doi: 10.1038/sj.eye.6702304, PMID 16543927

Chang AA, Li H, Broadhead GK, Luo K, Zhu M. Safety and efficacy of intravitreal preservative-free triamcinolone acetonide (Triesence) for macular edema. J Ocul Pharmacol Ther 2015;31:563-9. doi: 10.1089/ jop.2015.0021, PMID 26218262

Sørensen TL, Haamann P, Villumsen J, Larsen M. Intravitreal triamcinolone for macular oedema: Efficacy in relation to aetiology. Acta Ophthalmol Scand 2005;83:67-70. doi: 10.1111/j.1600- 0420.2004.00336.x, PMID 15715560

Spandau UH, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas JB. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 2005;89:999-1003. doi: 10.1136/bjo.2004.062596, PMID 16024853